Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svane

Showing results (711-720 of 811) with videos related to

Pageof 82
Sort By:
Journal for Immunotherapy of Cancer|March 15, 2019
Collagen density regulates the activity of tumor-infiltrating T cellsDorota E Kuczek, Anne Mette H Larsen, Marie-Louise Thorseth, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T Ten Ham, Maartje W Rohaan, Inge Jedema, et al.
Journal of Cancer Survivorship : Research and Practice|August 22, 2023
"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future careM D Egeler, E Boomstra, M W Rohaan, et al.
American Journal of Industrial Medicine|December 21, 2002
Estimating exposures in the asphalt industry for an international epidemiological cohort study of cancer riskIgor Burstyn, Paolo Boffetta, Timo Kauppinen, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cellsStine Emilie Weis-Banke, Thomas Landkildehus Lisle, Maria Perez-Penco, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort studyStine K Christensen, Mette L Winther, Ida J Laursen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 2, 2023
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)Inna M Chen, Marco Donia, Christopher A Chamberlain, et al.
American Journal of Epidemiology|August 26, 2003
Mortality from obstructive lung diseases and exposure to polycyclic aromatic hydrocarbons among asphalt workersIgor Burstyn, Paolo Boffetta, Dick Heederik, et al.
Journal for Immunotherapy of Cancer|July 2, 2021
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanomaTroels Holz Borch, Katja Harbst, Aynal Haque Rana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 StudyAlice Markussen, Julia S Johansen, Finn O Larsen, et al.
Pageof 82

Showing results (711-720 of 811) with videos related to

Sort By:
Pageof 82
Journal for Immunotherapy of Cancer|March 15, 2019
Collagen density regulates the activity of tumor-infiltrating T cellsDorota E Kuczek, Anne Mette H Larsen, Marie-Louise Thorseth, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T Ten Ham, Maartje W Rohaan, Inge Jedema, et al.
Journal of Cancer Survivorship : Research and Practice|August 22, 2023
"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future careM D Egeler, E Boomstra, M W Rohaan, et al.
American Journal of Industrial Medicine|December 21, 2002
Estimating exposures in the asphalt industry for an international epidemiological cohort study of cancer riskIgor Burstyn, Paolo Boffetta, Timo Kauppinen, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cellsStine Emilie Weis-Banke, Thomas Landkildehus Lisle, Maria Perez-Penco, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort studyStine K Christensen, Mette L Winther, Ida J Laursen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 2, 2023
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)Inna M Chen, Marco Donia, Christopher A Chamberlain, et al.
American Journal of Epidemiology|August 26, 2003
Mortality from obstructive lung diseases and exposure to polycyclic aromatic hydrocarbons among asphalt workersIgor Burstyn, Paolo Boffetta, Dick Heederik, et al.
Journal for Immunotherapy of Cancer|July 2, 2021
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanomaTroels Holz Borch, Katja Harbst, Aynal Haque Rana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2024
Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 StudyAlice Markussen, Julia S Johansen, Finn O Larsen, et al.
Pageof 82